Aastrom Adds Biologic-Device Offerings Through $6.5M Buy From Sanofi
This article was originally published in The Gray Sheet
Executive Summary
The deal will give cell-therapy firm Aastrom three products: Carticel, for treatment of articular cartilage defects; Epicel, a permanent skin replacement for full thickness burns; and MACI (matrix-induced autologous chondrocyte implant), an autologous chondrocyte implant approved in Europe.